Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer

I. Wolf, S. Levanon-Cohen, S. Bose, H. Ligumsky, B. Sredni, H. Kanety, M. Kuro-O, B. Karlan, B. Kaufman, H. P. Koeffler, T. Rubinek

Research output: Contribution to journalArticle

172 Citations (Scopus)

Abstract

Klotho is an anti-aging gene, which has been shown to inhibit the insulin and insulin-like growth factor 1 (IGF-1) pathways in mice hepatocytes and myocytes. As IGF-1 and insulin regulate proliferation, survival and metastasis of breast cancer, we studied klotho expression and activities in human breast cancer. Immunohistochemistry analysis of klotho expression in breast tissue arrays revealed high klotho expression in normal breast samples, but very low expression in breast cancer. In cancer samples, high klotho expression was associated with smaller tumor size and reduced KI67 staining. Forced expression of klotho reduced proliferation of MCF-7 and MDA-MB-231 breast cancer cells, whereas klotho silencing in MCF-7 cells, which normally express klotho, enhanced proliferation. Moreover, forced expression of klotho in these cells, or treatment with soluble klotho, inhibited the activation of IGF-1 and insulin pathways, and induced upregulation of the transcription factor CCAAT/enhancer-binding protein β, a breast cancer growth inhibitor that is negatively regulated by the IGF-1-AKT axis. Co-immunoprecipitation revealed an interaction between klotho and the IGF-1 receptor. Klotho is also a known modulator of the fibroblast growth factor (FGF) pathway, a pathway that inhibits proliferation of breast cancer cells. Studies in breast cancer cells revealed increased activation of the FGF pathway by basic FGF following klotho overexpression. Klotho did not affect activation of the epidermal growth factor pathway in breast cancer cells. These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer.

Original languageEnglish (US)
Pages (from-to)7094-7105
Number of pages12
JournalOncogene
Volume27
Issue number56
DOIs
StatePublished - Nov 27 2008

Fingerprint

Fibroblast Growth Factor 1
Somatomedins
Breast Neoplasms
Neoplasms
Fibroblast Growth Factors
Insulin
Breast
CCAAT-Enhancer-Binding Proteins
Somatomedin Receptors
Growth Inhibitors
MCF-7 Cells
Fibroblast Growth Factor 2
Immunoprecipitation
Epidermal Growth Factor
Human Activities
Muscle Cells
Hepatocytes
Transcription Factors
Up-Regulation
Immunohistochemistry

Keywords

  • Breast cancer
  • Insulin
  • Insulin growth factor-1
  • Klotho
  • Tumor suppressor

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Wolf, I., Levanon-Cohen, S., Bose, S., Ligumsky, H., Sredni, B., Kanety, H., ... Rubinek, T. (2008). Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene, 27(56), 7094-7105. https://doi.org/10.1038/onc.2008.292

Klotho : A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. / Wolf, I.; Levanon-Cohen, S.; Bose, S.; Ligumsky, H.; Sredni, B.; Kanety, H.; Kuro-O, M.; Karlan, B.; Kaufman, B.; Koeffler, H. P.; Rubinek, T.

In: Oncogene, Vol. 27, No. 56, 27.11.2008, p. 7094-7105.

Research output: Contribution to journalArticle

Wolf, I, Levanon-Cohen, S, Bose, S, Ligumsky, H, Sredni, B, Kanety, H, Kuro-O, M, Karlan, B, Kaufman, B, Koeffler, HP & Rubinek, T 2008, 'Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer', Oncogene, vol. 27, no. 56, pp. 7094-7105. https://doi.org/10.1038/onc.2008.292
Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H et al. Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene. 2008 Nov 27;27(56):7094-7105. https://doi.org/10.1038/onc.2008.292
Wolf, I. ; Levanon-Cohen, S. ; Bose, S. ; Ligumsky, H. ; Sredni, B. ; Kanety, H. ; Kuro-O, M. ; Karlan, B. ; Kaufman, B. ; Koeffler, H. P. ; Rubinek, T. / Klotho : A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. In: Oncogene. 2008 ; Vol. 27, No. 56. pp. 7094-7105.
@article{d1f638999978488f85bb7e598379d2c1,
title = "Klotho: A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer",
abstract = "Klotho is an anti-aging gene, which has been shown to inhibit the insulin and insulin-like growth factor 1 (IGF-1) pathways in mice hepatocytes and myocytes. As IGF-1 and insulin regulate proliferation, survival and metastasis of breast cancer, we studied klotho expression and activities in human breast cancer. Immunohistochemistry analysis of klotho expression in breast tissue arrays revealed high klotho expression in normal breast samples, but very low expression in breast cancer. In cancer samples, high klotho expression was associated with smaller tumor size and reduced KI67 staining. Forced expression of klotho reduced proliferation of MCF-7 and MDA-MB-231 breast cancer cells, whereas klotho silencing in MCF-7 cells, which normally express klotho, enhanced proliferation. Moreover, forced expression of klotho in these cells, or treatment with soluble klotho, inhibited the activation of IGF-1 and insulin pathways, and induced upregulation of the transcription factor CCAAT/enhancer-binding protein β, a breast cancer growth inhibitor that is negatively regulated by the IGF-1-AKT axis. Co-immunoprecipitation revealed an interaction between klotho and the IGF-1 receptor. Klotho is also a known modulator of the fibroblast growth factor (FGF) pathway, a pathway that inhibits proliferation of breast cancer cells. Studies in breast cancer cells revealed increased activation of the FGF pathway by basic FGF following klotho overexpression. Klotho did not affect activation of the epidermal growth factor pathway in breast cancer cells. These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer.",
keywords = "Breast cancer, Insulin, Insulin growth factor-1, Klotho, Tumor suppressor",
author = "I. Wolf and S. Levanon-Cohen and S. Bose and H. Ligumsky and B. Sredni and H. Kanety and M. Kuro-O and B. Karlan and B. Kaufman and Koeffler, {H. P.} and T. Rubinek",
year = "2008",
month = "11",
day = "27",
doi = "10.1038/onc.2008.292",
language = "English (US)",
volume = "27",
pages = "7094--7105",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "56",

}

TY - JOUR

T1 - Klotho

T2 - A tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer

AU - Wolf, I.

AU - Levanon-Cohen, S.

AU - Bose, S.

AU - Ligumsky, H.

AU - Sredni, B.

AU - Kanety, H.

AU - Kuro-O, M.

AU - Karlan, B.

AU - Kaufman, B.

AU - Koeffler, H. P.

AU - Rubinek, T.

PY - 2008/11/27

Y1 - 2008/11/27

N2 - Klotho is an anti-aging gene, which has been shown to inhibit the insulin and insulin-like growth factor 1 (IGF-1) pathways in mice hepatocytes and myocytes. As IGF-1 and insulin regulate proliferation, survival and metastasis of breast cancer, we studied klotho expression and activities in human breast cancer. Immunohistochemistry analysis of klotho expression in breast tissue arrays revealed high klotho expression in normal breast samples, but very low expression in breast cancer. In cancer samples, high klotho expression was associated with smaller tumor size and reduced KI67 staining. Forced expression of klotho reduced proliferation of MCF-7 and MDA-MB-231 breast cancer cells, whereas klotho silencing in MCF-7 cells, which normally express klotho, enhanced proliferation. Moreover, forced expression of klotho in these cells, or treatment with soluble klotho, inhibited the activation of IGF-1 and insulin pathways, and induced upregulation of the transcription factor CCAAT/enhancer-binding protein β, a breast cancer growth inhibitor that is negatively regulated by the IGF-1-AKT axis. Co-immunoprecipitation revealed an interaction between klotho and the IGF-1 receptor. Klotho is also a known modulator of the fibroblast growth factor (FGF) pathway, a pathway that inhibits proliferation of breast cancer cells. Studies in breast cancer cells revealed increased activation of the FGF pathway by basic FGF following klotho overexpression. Klotho did not affect activation of the epidermal growth factor pathway in breast cancer cells. These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer.

AB - Klotho is an anti-aging gene, which has been shown to inhibit the insulin and insulin-like growth factor 1 (IGF-1) pathways in mice hepatocytes and myocytes. As IGF-1 and insulin regulate proliferation, survival and metastasis of breast cancer, we studied klotho expression and activities in human breast cancer. Immunohistochemistry analysis of klotho expression in breast tissue arrays revealed high klotho expression in normal breast samples, but very low expression in breast cancer. In cancer samples, high klotho expression was associated with smaller tumor size and reduced KI67 staining. Forced expression of klotho reduced proliferation of MCF-7 and MDA-MB-231 breast cancer cells, whereas klotho silencing in MCF-7 cells, which normally express klotho, enhanced proliferation. Moreover, forced expression of klotho in these cells, or treatment with soluble klotho, inhibited the activation of IGF-1 and insulin pathways, and induced upregulation of the transcription factor CCAAT/enhancer-binding protein β, a breast cancer growth inhibitor that is negatively regulated by the IGF-1-AKT axis. Co-immunoprecipitation revealed an interaction between klotho and the IGF-1 receptor. Klotho is also a known modulator of the fibroblast growth factor (FGF) pathway, a pathway that inhibits proliferation of breast cancer cells. Studies in breast cancer cells revealed increased activation of the FGF pathway by basic FGF following klotho overexpression. Klotho did not affect activation of the epidermal growth factor pathway in breast cancer cells. These data suggest klotho as a potential tumor suppressor and identify it as an inhibitor of the IGF-1 pathway and activator of the FGF pathway in human breast cancer.

KW - Breast cancer

KW - Insulin

KW - Insulin growth factor-1

KW - Klotho

KW - Tumor suppressor

UR - http://www.scopus.com/inward/record.url?scp=58149229326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149229326&partnerID=8YFLogxK

U2 - 10.1038/onc.2008.292

DO - 10.1038/onc.2008.292

M3 - Article

C2 - 18762812

AN - SCOPUS:58149229326

VL - 27

SP - 7094

EP - 7105

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 56

ER -